Browsing by Author "Billah, Tashrif"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Publication
    Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis
    (2024) Wannan, Cassandra M. J.; Nelson, Barnaby; Addington, Jean; Allott, Kelly; Anticevic, Alan; Arango, Celso; Baker, Justin T.; Bearden, Carrie E.; Billah, Tashrif; Bouix, Sylvain; Broome, Matthew R.; Buccilli, Kate; Cadenhead, Kristin S.; Calkins, Monica E.; Cannon, Tyrone D.; Cecci, Guillermo; Chen, Eric Yu Hai; Cho, Kang Ik K; Choi, Jimmy; Clark, Scott R.; Coleman, Michael J.; Conus, Philippe; Cheryl M Corcoran, Cheryl M.; Cornblatt, Barbara; Diaz-Caneja, Covadonga M.; Dwyer, Dominic; Ebdrup, Bjorn H.; Ellman, Lauren M.; Fusar-Poli, Paolo; Galindo, Liliana; Gaspar, Pablo A.; Gerber, Carla; Birkedal Glenthøj, Louise; Glynn, Robert; Harms , Michael; Horton, Leslie E.; Kahn, René S.; Kambeitz-Ilankovic, Joseph; Kane, John M.; Castillo-Passi, Rolando
    This article describes the rationale, aims, and methodology of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international collaboration to date that will develop algorithms to predict trajectories and outcomes of individuals at clinical high risk (CHR) for psychosis and to advance the development and use of novel pharmacological interventions for CHR individuals. We present a description of the participating research networks and the data processing analysis and coordination center, their processes for data harmonization across 43 sites from 13 participating countries (recruitment across North America, Australia, Europe, Asia, and South America), data flow and quality assessment processes, data analyses, and the transfer of data to the National Institute of Mental Health (NIMH) Data Archive (NDA) for use by the research community. In an expected sample of approximately 2000 CHR individuals and 640 matched healthy controls, AMP SCZ will collect clinical, environmental, and cognitive data along with multimodal biomarkers, including neuroimaging, electrophysiology, fluid biospecimens, speech and facial expression samples, novel measures derived from digital health technologies including smartphone-based daily surveys, and passive sensing as well as actigraphy. The study will investigate a range of clinical outcomes over a 2-year period, including transition to psychosis, remission or persistence of CHR status, attenuated positive symptoms, persistent negative symptoms, mood and anxiety symptoms, and psychosocial functioning. The global reach of AMP SCZ and its harmonized innovative methods promise to catalyze the development of new treatments to address critical unmet clinical and public health needs in CHR
  • Thumbnail Image
    Publication
    Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample
    (2025) Allott, Kelly; Yassin, Walid; Alameda, Luis; Billah, Tashrif; Borders, Owen; Buccilli, Kate; Carrión, Ricardo E.; Castillo-Passi, Rolando I.; Cho, Kang Ik K.; Chin, Kota; Coleman, Michael J.; Colton, Beau-Luke; Corral, Sebastián; Dwyer, Dominic; Gundersen, Kristina Ballestad; Gur, Ruben C.; Hoftman, Gil D.; Jacobs, Grace R.; Kelly, Sinead; Lewandowski, Kathryn E.; Marcy, Patricia J.; Matneja, Priya; McLaughlin, Danielle; Nunez, Angela R.; Parsa, Setari; Penzel, Nora; Ray, Susan; Reinen, Jenna M.; Ruparel, Kosha; Sand, Michael S.; Santorelli, Gennarina; Seitz-Holland, Johanna; Spark, Jessica; Tamayo, Zailyn; Thompson, Andrew; Tod, Sophie; Wannan, Cassandra M. J.; Wickham, Alana; Wood, Stephen J.; Zoupou, Eirini
    Cognitive impairment occurs at higher rates in individuals at clinical high risk (CHR) for psychosis relative to healthy peers, and it contributes unique variance to multivariate prediction models of transition to psychosis. Such impairment is considered a core biomarker of schizophrenia. Thus, cognition is a key domain measured in the Accelerating Medicines Partnership® program for Schizophrenia (AMP SCZ initiative). The aim of this paper is to describe the rationale, processes, considerations, and final harmonization of the cognitive battery used in AMP SCZ across the two data collection networks. This battery comprises tests of general intellect and specific cognitive domains. We estimate premorbid intelligence at baseline and measure current intelligence at baseline and 2 years. Eight tests from the Penn Computerized Neurocognitive Battery (PennCNB), which measure verbal learning and memory, sensorimotor ability, attention, emotion recognition, working memory, processing speed, verbal memory, visual memory, and motor speed are administered repeatedly at baseline, and four follow-up timepoints over 2 years. Watch Dr. Kelly Allott and Dr. William S. Stone discuss their work and this article: https://vimeo.com/1023396087.
  • Thumbnail Image
    Publication
    The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures
    (2025) Mathalon, Daniel H.; Nicholas, Spero; Roach, Brian J.; Billah, Tashrif; Lavoie, Suzie; Whitford, Thomas; Hamilton, Holly K.; Addamo, Lauren; Anohkin, Andrey; Bekinschtein, Tristan; Belger, Aysenil; Buccilli, Kate; Cahill, John; Carrión, Ricardo E.; Damiani, Stefano; Dzafic, Ilvana; Ebdrup, Bjørn H.; Izyurov, Igor; Jarcho, Johanna; Jenni, Raoul; Jo, Anna; Kerins, Sarah; Lee, Clarice; Martin, Elizabeth A.; Mayol-Troncoso, Rocio; Niznikiewicz, Margaret A.; Parvaz, Muhammad; Pogarell, Oliver; Prieto-Montalvo, Julio; Rabin, Rachel; Roalf, David R.; Rogers, Jack; Salisbury, Dean F.; Shaik, Riaz; Shankman, Stewart; Stevens, Michael C.; Suen, Yi Nam; Swann, Nicole C.; Tang, Xiaochen; Castillo-Passi, Rolando I.
    Individuals at clinical high risk for psychosis (CHR) have variable clinical outcomes and low conversion rates, limiting development of novel and personalized treatments. Moreover, given risks of antipsychotic drugs, safer effective medications for CHR individuals are needed. The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) Program was launched to address this need. Based on past CHR and schizophrenia studies, AMP SCZ assessed electroencephalography (EEG)-based event-related potential (ERP), eventrelated oscillation (ERO), and resting EEG power spectral density (PSD) measures, including mismatch negativity (MMN), auditory and visual P300 to target (P3b) and novel (P3a) stimuli, 40-Hz auditory steady state response, and resting EEG PSD for traditional frequency bands (eyes open/closed). Here, in an interim analysis of AMP SCZ EEG measures, we assess test-retest reliability and stability over sessions (baseline, month-2 follow-up) in CHR (n=654) and community control (CON; n=87) participants. Reliability was calculated as Generalizability (G)-coefficients, and changes over session were assessed with paired t-tests. G-coefficients were generally good to excellent in both groups (CHR: mean =0.72, range=0.49–0.85; CON: mean=0.71, range=0.44–0.89). Measure magnitudes significantly (p < 0.001) decreased over session (MMN, auditory and visual target P3b, visual novel P3a, 40-Hz ASSR) and/or over runs within sessions (MMN, auditory/visual novel P3a and target P3b), consistent with habituation effects. Despite these small systematic habituation effects, test-retest reliabilities of the AMP SCZ EEG-based measures are sufficiently strong to support their use in CHR studies as potential predictors of clinical outcomes, markers of illness progression, and/or target engagement or secondary outcome measures in controlled clinical trials. Watch Dr Daniel H. Mathalon discuss their work and this article: https://vimeo.com/1066564687.

Implementado por OpenGeek Services